{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:09:10Z","timestamp":1740146950831,"version":"3.37.3"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970192"],"award-info":[{"award-number":["81970192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170195"],"award-info":[{"award-number":["82170195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Multiple myeloma (MM) is the second most prevalent hematologic malignancy which remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam, an aryl sulfonamide, has a potent anti-myeloma activity in vitro and in vivo. This study aims to explore the new mechanism of indisulam and investigate its potential use in combination with melphalan. We examined DNA damage in MM cells through various methods such as western blotting (WB), immunofluorescence, and comet assay. We also identified the role of topoisomerase II\u03b1 (TOP2A) using bioinformatic analyses. The impact of indisulam on the RNA and protein levels of TOP2A was investigated through qPCR and WB. Cell proliferation and apoptosis were assessed using CCK-8 assays, Annexin V\/PI assays and WB. We predicted the synergistic effect of the combination treatment based on calculations performed on a website, and further explored the effect of indisulam in combination with melphalan on MM cell lines and xenografts. RNA sequencing data and basic experiments indicated that indisulam caused DNA damage and inhibited TOP2A expression by decreasing transcription and promoting degradation via the proteasome pathway. Functional experiments revealed that silencing TOP2A inhibited cell proliferation and induced apoptosis and DNA damage. Finally, Indisulam\/melphalan combination treatment demonstrated a strong synergistic anti-tumor effect compared to single-agent treatments in vitro and in vivo. These findings suggest that combination therapies incorporating indisulam and melphalan have the potential to enhance treatment outcomes for MM.<\/jats:p>","DOI":"10.1371\/journal.pone.0299019","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T17:53:49Z","timestamp":1712685229000},"page":"e0299019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A"],"prefix":"10.1371","volume":"19","author":[{"given":"Chengyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-2444","authenticated-orcid":true,"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"1","key":"pone.0299019.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"RL Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"pone.0299019.ref002","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1024\/1661-8157\/a002984","article-title":"CME: Multiple Myeloma\u2014a Review","volume":"107","author":"M Brautigam","year":"2018","journal-title":"Praxis (Bern 1994)"},{"issue":"7","key":"pone.0299019.ref003","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"C Pawlyn","year":"2019","journal-title":"Blood"},{"issue":"10","key":"pone.0299019.ref004","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00001813-200211000-00002","article-title":"E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer","volume":"13","author":"C Van Kesteren","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"3","key":"pone.0299019.ref005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1010608317361","article-title":"Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells","volume":"19","author":"K Fukuoka","year":"2001","journal-title":"Invest New Drugs"},{"issue":"11","key":"pone.0299019.ref006","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2006.09.002","article-title":"Targeting tumor-associated carbonic anhydrase IX in cancer therapy","volume":"27","author":"A Thiry","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"pone.0299019.ref007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/13543784.12.2.283","article-title":"Indisulam: an anticancer sulfonamide in clinical development","volume":"12","author":"CT Supuran","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"pone.0299019.ref008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex","volume":"16","author":"DE Bussiere","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"15","key":"pone.0299019.ref009","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"SX Lu","year":"2021","journal-title":"Cell"},{"issue":"6336","key":"pone.0299019.ref010","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"T Han","year":"2017","journal-title":"Science"},{"issue":"1","key":"pone.0299019.ref011","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/s41467-021-24498-7","article-title":"Targeting KRAS4A splicing through the RBM39\/DCAF15 pathway inhibits cancer stem cells","volume":"12","author":"WC Chen","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0299019.ref012","doi-asserted-by":"crossref","first-page":"103025","DOI":"10.1016\/j.jbc.2023.103025","article-title":"The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1","volume":"299","author":"J Lu","year":"2023","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0299019.ref013","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.bjc.6603606","article-title":"A phase I and pharmacokinetic study of indisulam in combination with carboplatin","volume":"96","author":"C Dittrich","year":"2007","journal-title":"Br J Cancer"},{"issue":"6","key":"pone.0299019.ref014","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.clpt.6100344","article-title":"PK\/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression","volume":"83","author":"AS Zandvliet","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"pone.0299019.ref015","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00280-012-1844-8","article-title":"Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment","volume":"69","author":"Y Ozawa","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"pone.0299019.ref016","doi-asserted-by":"crossref","first-page":"e0273182","DOI":"10.1371\/journal.pone.0273182","article-title":"Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity","volume":"17","author":"Z Pogacar","year":"2022","journal-title":"PLoS One"},{"issue":"13","key":"pone.0299019.ref017","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"R Assi","year":"2018","journal-title":"Cancer"},{"issue":"10272","key":"pone.0299019.ref018","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"N van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"pone.0299019.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10091841","article-title":"Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches","volume":"10","author":"A Poczta","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"pone.0299019.ref020","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2016-01-691618","article-title":"DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7","volume":"128","author":"M Gkotzamanidou","year":"2016","journal-title":"Blood"},{"issue":"12","key":"pone.0299019.ref021","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1159\/000520504","article-title":"Current Treatment Approaches to Newly Diagnosed Multiple Myeloma","volume":"44","author":"S Ghandili","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"44","key":"pone.0299019.ref022","doi-asserted-by":"crossref","first-page":"eadd4920","DOI":"10.1126\/sciadv.add4920","article-title":"Untangling the roles of TOP2A and TOP2B in transcription and cancer","volume":"8","author":"L Uuskula-Reimand","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"pone.0299019.ref023","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13059-016-1043-8","article-title":"Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders","volume":"17","author":"L Uuskula-Reimand","year":"2016","journal-title":"Genome Biol"},{"key":"pone.0299019.ref024","doi-asserted-by":"crossref","first-page":"12638","DOI":"10.1038\/ncomms12638","article-title":"RNF168 and USP10 regulate topoisomerase IIalpha function via opposing effects on its ubiquitylation","volume":"7","author":"KKN Guturi","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0299019.ref025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1245\/s10434-010-1198-6","article-title":"Metaplastic breast cancer: to radiate or not to radiate?","volume":"18","author":"WH Tseng","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"pone.0299019.ref026","doi-asserted-by":"crossref","first-page":"103545","DOI":"10.1016\/j.jprot.2019.103545","article-title":"pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate","volume":"210","author":"X Jia","year":"2020","journal-title":"J Proteomics"},{"issue":"7","key":"pone.0299019.ref027","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1007\/s13277-014-1819-y","article-title":"Overexpression of HCC1\/CAPERalpha may play a role in lung cancer carcinogenesis","volume":"35","author":"Y Chai","year":"2014","journal-title":"Tumour Biol"},{"issue":"8","key":"pone.0299019.ref028","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/cc.28156","article-title":"CAPER, a novel regulator of human breast cancer progression","volume":"13","author":"I Mercier","year":"2014","journal-title":"Cell Cycle"},{"issue":"4","key":"pone.0299019.ref029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13402-012-0088-2","article-title":"CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression","volume":"35","author":"AH Sillars-Hardebol","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"pone.0299019.ref030","first-page":"311","article-title":"Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity","volume":"20","author":"H Hirota","year":"2002","journal-title":"Int J Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T17:54:06Z","timestamp":1712685246000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299019"}},"subtitle":[],"editor":[{"given":"Salman","family":"Shakil","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}